Deubiquitinating enzymes as cancer biomarkers: new therapeutic opportunities?

Naresh Poondla1,*, Arun Pandian Chandrasekaran1,*, Kye-Seong Kim1,2,* & Suresh Ramakrishna1,2,*

1Department of Biomedical Science, Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul 04763, 2College of Medicine, Hanyang University, Seoul 04763, Korea

Cancer remains a life-threatening disease and accounts for the major mortality rates worldwide. The practice of using biomarkers for early detection, staging, and customized therapy may increase cancer patients' survival. Deubiquitinating enzymes (DUBs) are a family of proteases that remove ubiquitin tags from proteins of interest undergoing proteasomal degradation. DUBs play several functional roles other than deubiquitination. One of the important roles of DUBs is regulation of tumor progression. Several reports have suggested that the DUB family members were highly-elevated in various cancer cells and tissues in different stages of cancer. These findings suggest that the DUBs could be used as drug targets in cancer therapeutics. In this review, we recapitulate the role of the DUB family members, including ubiquitin-specific protease, otubain protease, and important candidates from other family members. Our aim was to better understand the connection between DUB expression profiles and cancers to allow researchers to design inhibitors or gene therapies to improve diagnosis and prognosis of cancers. [BMB Reports 2019; 52(3): 181-189]

INTRODUCTION

Cancer is one of the major diseases causing death globally, accounting for 8.2 million deaths in 2012 (1). Recent advances in molecular and cellular biology have played important roles in understanding cancer and breakthroughs that have been being translated into therapy. Because of these recent developments, genes that are involved in cancer are being unraveled (2, 3). Most of the known cancer genes were originally identified by genetic evidence. A protein that is encoded by a cancer gene typically regulates cell proliferation and differentiation and eventually leads to cell death or apoptosis. Mutations that lead to oncogenesis typically occur in genes that mediate DNA repair mechanisms (4).

Ubiquitin proteasome pathway

The post-translational attachment of ubiquitin is a modification that can determine a protein’s fate. While ubiquitin itself is a small conserved protein, its covalent conjugation to protein substrates and to other ubiquitin molecules is a tightly-controlled process involving complex cellular machinery. Perhaps the most prominent and well-known function of ubiquitin is to target a protein for degradation by the 26S proteasome. Degradation can be accomplished via an isopeptide bond formation between the carboxy-terminal glycine (Gly) site on the ubiquitin and an ε-amino group of the lysine (Lys) side chains of a protein substrate. The ubiquitin-substrate system is further diversified via the process of polyubiquitination, during which a ubiquitin molecule’s C-terminal Gly is conjugated with one of the seven Lys residues on another ubiquitin (Lys6, Lys11, Lys27, Lys29, Lys33, Lys48, or Lys63) or with the N-terminus to form linear chains. The ubiquitin-proteasome protein degradation pathway is comprised of ubiquitin, a three-enzyme ubiquitination complex, the intracellular protein ubiquitination targets, and the proteasome that is the organelle of protein degradation, as well as ubiquitin-activating enzymes (E1), ubiquitin-conjugating enzymes (E2), and ubiquitin ligases (E3).

Deubiquitinating enzymes

Deubiquitinating enzymes (DUBs) are proteases that reverse protein ubiquitination, a process which is significant for normal homeostasis. DUBs have four distinct mechanisms of action: 1) processing of ubiquitin precursors, 2) recycling of ubiquitin molecules during ubiquitination, 3) cleavage of polyubiquitin chains, and 4) reversal of ubiquitin conjugation (Fig. 1). DUBs regulate several cellular functions, including proteasome-dependent and lysosome-dependent proteolysis, gene expression, cell cycle progression, chromosome segrega-
DUBs as cancer biomarkers
Naresh Poondla, et al.

Fig. 1. Various catalytic mechanisms exhibited by DUBs. DUBs can unknot ubiquitin conjugation by cleaving the bond between ubiquitin molecules and ubiquitin-target complexes, editing ubiquitin chains to remove one or more ubiquitin molecules, and finally, recycling of ubiquitin molecules in the ubiquitin-proteasome pathway.

Fig. 1. Various catalytic mechanisms exhibited by DUBs. DUBs can unknot ubiquitin conjugation by cleaving the bond between ubiquitin molecules and ubiquitin-target complexes, editing ubiquitin chains to remove one or more ubiquitin molecules, and finally, recycling of ubiquitin molecules in the ubiquitin-proteasome pathway.

DUBs as cancer biomarkers
Naresh Poondla, et al.

 Various catalytic mechanisms exhibited by DUBs. DUBs can unknot ubiquitin conjugation by cleaving the bond between ubiquitin molecules and ubiquitin-target complexes, editing ubiquitin chains to remove one or more ubiquitin molecules, and finally, recycling of ubiquitin molecules in the ubiquitin-proteasome pathway.

Fig. 1. Various catalytic mechanisms exhibited by DUBs. DUBs can unknot ubiquitin conjugation by cleaving the bond between ubiquitin molecules and ubiquitin-target complexes, editing ubiquitin chains to remove one or more ubiquitin molecules, and finally, recycling of ubiquitin molecules in the ubiquitin-proteasome pathway.

Approximately 100 DUBs are encoded in the human genome (10). Based on the organization of the catalytic domain, DUBs are classified into distinct families, the vast majority of which are cysteine proteases. These include ubiquitin-specific proteases (USPs), ubiquitin C-terminal hydrolases (UCHs), ovarian tumor proteases (OTUs), Machado-Joseph disease proteases (MJDs), Jab1/Mov34/Mpr1 (JAMM) metalloproteases, and the recently-discovered MIU-containing novel DUB family, (MINDY) proteases (11).

UBIQUITIN-SPECIFIC PROTEASE FAMILY

USP2
USP2a, an isoform of USP2, is an androgen-regulated DUB that deubiquitinates the antiapoptotic proteins such as fatty acid synthase, Mdm2, and MdmX (12). USP2a expression is increased in glioma cells compared to normal brain tissues, which suggests that USP2a may correlate with malignant glioma progression, and therefore may be an effective marker for glioma prognosis (13). Furthermore, USP2 plays a role in tumor metastasis by modulating the activity or expression of MMP2, suggesting its use as a potential breast cancer marker (13).

USP4
USP4 has been strongly implicated in the regulation of tumor metastasis in breast cancer (14), liver cancer (15), and colorectal cancer (16). USP4 is significantly increased in melanoma and plays an oncogenic role by simultaneously inhibiting stress-induced cell apoptosis and promoting tumor metastasis (17). USP4 is an important protein that facilitates hepatocellular carcinoma (HCC) progression by stabilizing CYP2A through deubiquitination and activating MAPK/CrklII signaling pathways, indicating that USP4 may act as a novel marker to predict prognosis and present a therapeutic opportunity for HCC (18). In breast cancer, USP4 promotes the migration and invasion of breast cancer cells via RLX-mediated TGF-β/Smad2/MMP-9 pathways, providing an attractive target for breast cancer therapy (19). The above results suggested that overexpression of USP4 in various cancers is due to the stabilization of other oncogenes in the respective cancer types. Thus, targeting USP4 as a biomarker could be useful for the early diagnosis of cancer.

USP5
USP5 acts as an exopeptidase that hydrolyzes isopeptide bonds in poly-ubiquitin from their free carboxy-terminal ends to produce monoubiquitin (20). USP5 knockdown suppressed cell proliferation, migration, and drug resistance and induced apoptosis, while USP5 overexpression promoted colony formation, migration, drug resistance, and tumorigenesis (21). USP5 plays a critical role in hepatocarcinogenesis through inactivation of the p14-p53 signaling pathway contributing to tumorigenesis and drug resistance, which provides a clue that USP5 could be a potential therapeutic target for HCC (22). In pancreatic cancer, USP5 plays a critical role in tumorigenesis and progression by stabilizing the FoxM1 protein, showing therapeutic potential against pancreatic cancer (23).

USP7
USP7, also known as herpes-associated ubiquitin-specific protease (HAUSP), was originally identified as an ubiquitin-specific protease that binds to a viral-encoded protein, called Vmw110 (24). HAUSP protein can bind to the herpes simplex virus type 1 (HSV-1) regulatory protein, which is known as infected cell polypeptide (ICPO). In epithelial ovarian cancer (EOC), USP7 and MARCH7 proteins are differentially expressed and the combination of USP7 and MARCH7 expression may function as promising biomarkers for EOC prognosis (25). HCC is one of the most dominant cancer types in the world. High expression of USP7 mRNA and protein levels in HCC tissues compared to normal liver samples has been reported (26). Cell-based assays have suggested that USP7 expression confers cell proliferation, migration, and invasion capabilities. These data suggest that USP7 could be a novel independent prognostic marker for HCC. Recently, a study suggested that USP7 deubiquitinates Ki-67, and thereby promotes cell proliferation in non-small-cell lung cancer (NSCLC) (27). Here, both Ki-67 and USP7 were expressed in NSCLC cells. Statistical data revealed a strong correlation between USP7 and Ki-67 levels. In contrast, siRNA targeting
USP7 increased the ubiquitination of Ki-67 and led to delayed tumor growth. The above evidence suggests that USP7 could be an important therapeutic target in various cancer types.

**USP8**
USP8 belongs to the USP superfamily of DUBs targeting several substrates (28), including smoothened (29), frizzled (30), neuregulin receptor degradation protein-1, and receptor tyrosine kinase. Recently, the expression profile of USP8 in cervical squamous cell carcinoma (CSCC) has been studied (31). USP8 was upregulated in CSCC tissue samples compared to non-cancerous cervical tissues. Also, high expression of USP8 was associated with tumor stage and was recognized as an independent prognostic marker for CSCC. USP8 increased the ubiquitination of Ki-67 and led to delayed tumor growth. The above evidence suggests that USP7 could be an important therapeutic target in various cancer types.

**USP10**
USP10, also known as UBPO, is a protein consisting of 798 amino acids and was originally discovered as a DUB that interacts with the Ras-GAP SH3 domain-binding protein (32). Increased USP10 expression has been detected in some breast cancer and glioblastoma samples. Overexpression of USP10 has been associated with poor prognosis for glioblastoma multiforme patients, while decreased USP10 has been observed in gastric cancer tissues, and its downregulation has been associated with invasion, metastasis, and poor prognosis of gastric cancer. Current studies have also shown that USP10 suppressed proliferation and growth of pancreatic cancer cells.

Therefore, USP10, as a novel DUB, has a crucial role in various pathological processes of tumors. In gastric cancer (GC), clinical samples and cell lines showed low-level expression of USP10, and negative USP10 expression was associated with a marked propensity toward gastric wall invasion, lymph node metastasis, highly malignant biological behavior, and poor survival. USP10 identification in GC can potentially serve as a new prognostic indicator predicting the treatment outcome for GC patients.

**USP22**
USP22 is a novel DUB that has been related to cell cycle progression, therapy resistance, and metastasis. The expression frequency of USP22 was extremely high in HCC compared to normal liver tissues (31). Elevated levels of USP22 represented poor HCC patient survival and have also been associated with greater mortality in patients with advanced tumor stages, shown by Kaplan-Meier analysis. As revealed by multivariate analyses, USP22 is a self-regulating prognostic marker in HCC. Several other researchers have reported that USP22 was overexpressed in salivary duct carcinoma (33) and esophageal squamous cell carcinoma (34). The above findings indicate that high USP22 expression might be an important factor in tumor progression and may serve as an independent molecular marker.

**USP32**
USP32 is a highly-conserved and uncharacterized gene, located on the 17q23.1-17q23.2 chromosomal band (35). USP32 was present in 22% of primary breast cancer tumors.

**Fig. 2.** DUBs involved in the regulation of oncogenic pathways. Inhibition of specific DUBs leads to decreased cancer proliferation, drug resistance, and delayed metastasis.
DUBs as cancer biomarkers
Naresh Poondla, et al.

compared to non-cancerous mammary tissues, and 50% of breast cancer cell lines. Endogenously, USP32 was highly-elevated in the MCF7 cell line, and no mutation was detected in this cell line, indicating that the wild-type gene was overexpressed. Additionally, USP32 has a role in human small cell lung cancer (SCLC) (36). USP32 is highly-expressed in SCLC tissue samples compared to normal tissues. During the disease aggravation stage, USP32 in vitro caused reduced migration and proliferation rates of SCLC cells. Also, this downregulation arrested the cells at the G0/G1 phase by elevating p21 and decreasing CDK4-cyclin D1 complex levels. Cleaved caspase-3 and cleaved-PARP were activated when the USP32 gene was silenced, eventually leading to apoptosis by altering the epithelial-mesenchymal transition. Overall, USP32 could be a potential target for breast and lung cancers.

**OTUBAIN PROTEASE FAMILY**

**OTUB1**
The OTU domain-containing ubiquitin aldehyde-binding protein 1 (OTUB1) belongs to the OTU DUB family and is reported to be involved in various malignancies (37-40). Recently, the role of OTUB1 in human gliomas has been elucidated (41). Immunoblot and immunohistochemical experiments validated that glioma tissues overexpress OTUB1 genes and statistical studies showed that the expression pattern of OTUB1 was highly-linked to the WHO grades of the gliomas. On the other hand, downregulation of OTUB1 was linked to poor migration and also elevated EMT-related protein E-cadherin expression. Thus, OTUB1 might be involved in the regulation of ECM stability. The above results suggested that OTUB1 could be an important cancer marker in gliomas and other malignancies and could be a potential target for successful cancer therapy.

**A20**
A20 is a DUB that was originally found to be involved in autoimmunity and inflammation (42). However, a recent study proposed that A20 is highly involved in cancer metastasis (43). Here, A20 overexpression leads to metastasis of basal-like breast cancer by monoubiquitinating Snail1. In human basal-like breast cancers, A20 was significantly overexpressed and accounted for cancer metastasis. Additionally, A20 mediates TGFB1-induced EMT of breast cancers by monoubiquitylating Snail1. Reports also suggested that the transient knockdown of A20 displayed decreased lung cancer metastasis in orthotopic breast cancer models and mouse xenografts.

| DUB     | Inhibitor(s)                                      | Disease Indication     | Stage of development | References |
|---------|---------------------------------------------------|------------------------|----------------------|------------|
| USP1    | ML323, Pimozide                                   | Oncology               | Preclinical           | (50)       |
| USP2    | ML364                                             | Inflammation           | Preclinical           | (50)       |
| USP4    | Vialinin A                                        | Inflammation and oncology | Preclinical           | (51, 52)  |
| USP5    | WP1130                                            |                        | Preclinical           |            |
| USP7    | ADC-01, ADC-03                                    | Oncology, Immuno-oncology | Preclinical           | (53)       |
|         | HBX41108                                          | Oncology, Immuno-oncology | Preclinical           | (54, 55)  |
|         | P5091                                             | Oncology, Immuno-oncology | Preclinical           | (56)       |
|         | P22077                                            | Oncology, Immuno-oncology | Preclinical           | (56)       |
| USP8    | 9-Ethoxyimino-9H-indeno (1,2-b) pyra-zine-2,3-dicarbonitrile | Oncology               | Preclinical           | (56)       |
| USP9X   | WP1130                                            | Oncology               | Preclinical           | (57)       |
| USP10 and USP13 | Spautin 1                                    | Inflammation           | Preclinical           | (57)       |
| USP11   | Mitoantrone                                       | Oncology               | Preclinical           | (58)       |
| USP14   | 1U1, b-AP15, VLX1370, wp1130                      | Neurodegeneration       | Preclinical           | (59)       |
| USP20   | GSK2643943A                                       | Oncology               | Preclinical           | (60)       |
| USP30   | 15-oxospiramilaactone                             | Neurodegeneration       | Preclinical           | (61)       |
| USP47   | P5091                                             | Cancer                 | Preclinical           | (56)       |
| UCH37   | WP1130                                            | Cancer                 | Preclinical           | (57)       |
| UCHL5   | b-AP15                                            | Neurology              | Preclinical           | (62)       |
| UCHL1   | LDN-57444                                        | Cancer                 | Preclinical           | (63)       |
| UCHL3   | LDN-57444                                        | Cancer                 | Preclinical           | (64)       |
| UCHL5   | TCD, b-AP15                                       | Cancer                 | Preclinical           | (62, 65)  |
| UCH37   | WP1130                                            | Cancer                 | Preclinical           | (57)       |
DUB INHIBITORS

A number of reports have described the identification and utility of small molecule DUB inhibitors as anticancer agents (44). Inhibition of DUBs leads to cellular changes, such as (i) aggregation of polyubiquitinated protein molecules, (ii) reduction in the group of monomeric ubiquitin moieties, (iii) increased rates of polyubiquitin assembly, (iv) overall reduction in DUB events, and (v) altered cellular activities, such as DUB regulation of oncoproteins (45). Generally, DUB inhibition leads to impaired proteasome function and aggregation of mistfolded functional proteins, resulting in cellular toxicity and death. DUBs that control oncogenic proteins can be targeted by small molecules that inhibit deubiquitinating activity via UPS degradation, while DUBs that control tumor suppressors can be targeted by increasing the deubiquitinating activity, thus inhibiting oncogenic progression. Several studies have been carried out to design small molecule DUB inhibitors because they are simpler to design than enzyme activators, using substrate modeling and competitive inhibition (46, 47). A schematic representation of DUB inhibition on relevant pathways is depicted in Fig. 2.

An extensive study was carried out to discover drugs that inhibit DUBs and resulted in the discovery of ubiquitin

| Disease                        | DUB                        | References |
|--------------------------------|----------------------------|------------|
| Gliomas                        | USP2a, USP22, USP44, BAP1, OTUB1 | (41, 66, 67) |
| Breast cancer                  | USP2, USP22, USP37         | (68, 69)   |
| Hepatocellular carcinoma       | USP4, USP5, USP11, USP22, UCHL1, A20, OTUB1 | (70, 71)   |
| Esophageal cancer              | USP4                       | (72)       |
| Melanoma                       | USP4                       | (72)       |
| Pancreatic cancer              | USP5                       | (72)       |
| Epithelial ovarian cancer      | USP7                       | (72)       |
| Lung adenocarcinoma            | USP8                       | (73, 74)   |
| Gastric carcinoma              | USP10                      | (75)       |
| Endometrial cancer             | USP14                      | (75)       |
| Non-small cell lung carcinoma  | USP17, USP22, OTUD7B, OTUD68 | (76, 77)   |
| Renal clear cell carcinoma     | USP21                      | (76)       |
| Muscle invasive bladder cancer | USP18                      | (79)       |
| Cervical cancer                | USP22                      | (80)       |
| Oral squamous cell carcinoma   | USP22                      | (81)       |
| Papillary thyroid carcinoma    | USP22, USP33               | (82, 83)   |
| Salivary duct carcinoma        | USP22                      | (84)       |
| Esophageal squamous cell carcinoma | USP22                   | (34)       |
| Salivary adenoid cystic carcinoma | USP22                   | (34)       |
| Bladder cancer                 | USP28                      | (84)       |
| Colorectal cancer              | USP33, OTUB1, MYSM1        | (85, 86)   |
| Prostate cancer                | USP39                      | (87)       |
| Malignant peritoneal mesothelioma | BAP1                    | (88)       |
| Triple-negative breast cancer  | OTUD7B                     | (89)       |
| Pancreatic ductal adenocarcinoma | UCHL5                   | (90)       |
| Gastric cardiac adenocarcinoma | UCHL1                     | (91)       |
| Cholangiocarcinoma             | UCHL1                      | (91)       |
| Aggressive multiple myeloma    | UCHL1                      | (92)       |
| Neuronal apoptosis             | USP4, UCHL1               | (93, 94)   |
| Cardiac hypertrophy            | USP4                       | (95)       |
| Aneurysmal bone cyst           | USP6                       | (96)       |
| Pancreatic beta cells          | UCHL1                      | (97)       |
| Aneurysmal subarachnoid hemorrhage | UCHL1                | (98)       |
| Neuronal biomarker             | UCHL1                      | (98)       |
| Traumatic brain injury         | UCHL1                      | (99)       |
| Pancreatic neuroendocrine tumors | UCHL1                   | (100)      |

Table 2. DUBs expressed in various types of cancer
aldehyde (Ubal) and ubiquitin vinyl sulfone (UbVS) (48). Due to their high molecular weights, peptidic nature, and lack of specificity, these compounds were not pharmacologically sustainable (48). The UCH family of proteins is involved in deubiquitination by removing ubiquitin from C-terminal adducts (48). Hence, researchers have made an effort to design their inhibitors and ended up with an isatin O-acyl oximes series (48). They are competitive and capable of directly targeting the active site with minimal IC50 values. Basically, UCH-L1 decreases cell proliferation in neuroblastoma cells; when this inhibitor is applied, cell proliferation is elevated. Thus, the data support the anti-proliferative nature of UCH-L1 proteins. A novel proteasome-inhibitory compound has been synthesized, called b-AP15 (49). The b-AP15 small molecule specifically inhibits USP14 and UCHL5 which are associated with 19S RP. Additionally, the compound b-AP15 showed effective anti-cancer responses against other refractory cancer types. Inhibitors targeting other important DUBs are described in Table 1.

CONCLUSION
This review delivers a comprehensive report of the DUBs for cancer diagnosis and prognosis. Recent developments of cancer therapies and the promptness of their application to clinical use for various tumors validate the prospects of exploiting DUBs as targets for drug development. The expression profiles of several DUBs in different cancer types are discussed in Table 2. Moreover, these DUBs exert their function through binding to their proteins, which can be targeted. In other cases, the DUB itself seems to be an excellent drug target. More detailed information on the roles, localization, regulation, and substrates of DUBs will help researchers understand their roles in oncogenesis and clinical applications of their inhibitors. Enhanced improvement in small molecule pharmacological development against DUBs will permit greater success in the treatment of cancer and other deadly diseases.

ACKNOWLEDGEMENTS
This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF), which is funded by the Ministry of Education (2017R1A2B2008727, 2018M3A9H3022412 and 2017M3A9B3061830) and Bio and Medical Technology Development Program of the National Research Foundation (NRF) and funded by the Korean government (MSIP and MOHW) (2017M3A9E4048172).

CONFLICTS OF INTEREST
The authors have no conflicting interests.

REFERENCES
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A (2012) Global cancer statistics. CA Cancer J Clin 65, 87-108
2. Li J, Shen H and Himmel KL (1999) Leukaemia disease genes: large-scale cloning and pathway predictions. Nat Genet 23, 348-353
3. Hansen GM, Skapura D and Justice MJ (2000) Genetic profile of insertion mutations in mouse leukemias and lymphomas. Genome Res 10, 237-243
4. Fishel R, Lescoe MK, Rao MR et al (1993) The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75, 1027-1038
5. Sharma A, Alswillah T, Singh K et al (2018) USP14 regulates DNA damage repair by targeting RNF168-dependent ubiquitination. Autophagy 14, 1976-1990
6. Chandraekaran AP, Suresh B, Kim HH, Kim KS and Ramakrishna S (2017) Concise Review: Fate Determination of Stem Cells by Deubiquitinating Enzymes. Stem Cells 35, 9-16
7. Lork M, Verhelst K and Beyer R (2017) CYLD, A20 and OTULIN deubiquitinases in NF-kB signaling and cell death: so similar, yet so different. Cell Death Differ 24, 1172-1183
8. Darling S, Fielding AB, Sabat-Pohtschich D, Prior IA and Coulson JM (2017) Regulation of the cell cycle and centrosome biology by deubiquitylases. Biochem Soc Trans 45, 1125-1136
9. Jacq X, Kemp M, Martin NMB and Jacobson SP (2013) Deubiquitylating Enzymes and DNA Damage Response Pathways. Cell Biochem Biophys 67, 25-43
10. Nijman SMB, Luna-Vargas MPA and Velds A (2005) A genomic and functional inventory of deubiquitinating enzymes. Cell 123, 773-786
11. Abdul Rehman SA, Kristriyanto YA, Choi SY et al (2016) MINDY-1 Is a Member of an Evolutionarily Conserved and Structurally Distinct New Family of Deubiquitinating Enzymes. Mol Cell 63, 146-155
12. Priolo C, Tang D, Brachamandan M et al (2006) The isopeptidase USP2a protects human prostate cancer from apoptosis. Cancer Res 66, 8526-8532
13. Qu Q, Mao Y, Xiao D, et al (2013) USP2 promotes stem cell migration and invasion in triple negative breast cancer cell lines. Tumor Biol 36, 5415-5423
14. Zhang L, Zhou F, Dralch Y et al (2012) USP4 is regulated by AKT phosphorylation and directly deubiquitylates TGF-β type i receptor. Nat Cell Biol 14, 717-726
15. Seibold MA and Schwartz DA (2011) The authors reply. N Engl J Med 364, 1503-1512
16. Ying C, Lu X, Guo P, et al (2016) Ubiquitin-specific protease 4-mediated deubiquitination and stabilization of PRL-3 is required for potentiating colorectal oncogenesis. Cancer Res 76, 83-95
17. Guo W, Ma J, Pei T et al (2018) Up-regulated deubiquitinase USP4 plays an oncogenic role in melanoma. J Cell Mol Med 22, 2944-2954
18. Li T, Yan B, Ma Y et al (2018) Ubiquitin-specific
protease 4 promotes hepatocellular carcinoma progression via cyclophilin A stabilization and deubiquitination. Cell Death Dis 9, 148-165
19. Cao WH, Liu XP, Meng SL et al (2016) USP4 promotes invasion of breast cancer cells via Relaxin/TGF-β1/ Smad2/4/3/5 signal. Eur Rev Med Pharmacol Sci 20, 1115-1122
20. Hicke L (2001) Protein regulation by monoubiquitin. Nat Rev Mol Cell Biol 2, 195-201
21. Tang B, Tang F, Li B et al (2015) High USP22 expression indicates poor prognosis in hepatocellular carcinoma. Oncotarget 6, 12654-12667
22. Liu Y, Wang W, Lu Y et al (2017) Usp5 functions as an oncogene for stimulating tumorigenesis in hepatocellular carcinoma 8, 50635-50664
23. Li XY, Wu HY, Mao XF, Jiang LX and Wang YX (2018) USP5 promotes tumorigenesis and progression of pancreatic cancer by stabilizing FoxM1 protein. Biochem Biophys Res Commun 492, 48-54
24. Cheon KW and Baek KH (2006) HAUSP as a therapeutic target for hematopoietic tumors (Review). Int J Onco 28, 1209-1215
25. Zhang L, Wang H, Tian L and Li H (2016) Expression of USP7 and MARCH7 Is Correlated with Poor Prognosis in Epithelial Ovarian Cancer. Tohoku J Exp Med 239, 165-175
26. Wang X, Zhang Q, Wang Y, Zhuang H and Chen B (2018) Clinical Significance of Ubiquitin Specific Protease 7 (USP7) in Predicting Prognosis of Hepatocellular Carcinoma and its Functional Mechanisms. Med Sci Monit 24, 1742-1750
27. Zhang C, Lu J, Zhang Q-W et al (2016) USP7 promotes cell proliferation through the stabilization of Ki-67 protein in non-small cell lung cancer cells. Int J Biochem Cell Biol 79, 209-221
28. Fraile JM, Quesada V, Rodríguez D, Freije JMP and López-Otín C (2012) Deubiquitinasines in cancer: New functions and therapeutic options. Oncogene 31, 2373-2388
29. Xia R, Jia H, Fan J, Liu Y and Jia J (2012) USP8 promotes smoothened signaling by preventing its ubiquitination and changing its subcellular localization. PLoS Biol 10, e1001238
30. Mukai A, Yamamoto-Hino M, Awano W, Watanabe W, Komada M and Goto S (2010) Balanced ubiquitylation of Snail1. Nat Cell Biol 12, 165-175
31. Yan M, Zhao C, Wei N, Wu X, Cui J and Xing Y (2018) High Expression of Ubiquitin-Specific Protease 8 (USP8) Is Associated with Poor Prognosis in Patients with Cervical Squamous Cell Carcinoma. Med Sci Monit 24, 4934-4943
32. Soncini C, Berdo I and Draetta G (2001) Ras-GAP SH3 domain binding protein (G3BP) is a modulator of USP10. Oncogene 20, 3869-3879
33. Piao S, Mu J, Wang W et al (2013) Increased expression of USP22 is associated with disease progression and patient prognosis of salivary duct carcinoma. Oral Oncol 49, 796-801
34. Li J, Wang Z and Li Y (2012) USP22 nuclear expression is significantly associated with progression and unfavorable clinical outcome in human esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 138, 1291-1297
35. Akhavantabasi S, Akman HB, Sapmaz A, Keller J, Petty EM and Eson AE (2010) USP32 is an active, membrane-bound ubiquitin protease overexpressed in breast cancers. Mammm Genom 21, 388-397
36. Hu W, Wei H, Li K, Li P, Lin J and Feng R (2017) Downregulation of USP32 inhibits cell proliferation, migration and invasion in human small cell lung cancer. Cell Prolif 50, e12343
37. Baietti MF, Simicke M, Abbasi Ashbagh L et al (2016) OTUB1 triggers lung cancer development by inhibiting RAS monoubiquitination. EMBO Mol Med 8, 288-303
38. Stanisic V, Malovannaya A, Qin J, Lonard DM and O'Malley BW (2009) OTU Domain-containing Ubiquitin Aldehyde-binding Protein 1 (OTUB1) Deubiquitimates Estrogen Receptor (ER) α and Affects ERα Transcriptional Activity. J Biol Chem 284, 16135-16145
39. Zhang Y, Hu R, Wu H et al (2012) OTUB1 Overexpression in Mesangial Cells Is a Novel Regulator in the Pathogenesis of Glomerulonephritis through the Decrease of DCN Level. PLoS One 7, e29654
40. Weng W, Zhang Q, Xu M et al (2016) OTUB1 promotes tumor invasion and predicts a poor prognosis in gastric adenocarcinoma. Am J Transl Res 8, 2234-2244
41. Xu L, Li J, Bao Z et al (2017) Silencing of OTUB1 inhibits migration of human glioma cells in vitro. Neuro-pathology 37, 217-226
42. Catrysse L, Vereecke L, Beyaert R and van Loo G (2014) A20 in inflammation and autoimmunity. Trends Immunol 35, 22-31
43. Lee JH, Jung SM, Yang KM et al (2017) A20 promotes metastasis of aggressive basal-like breast cancers through multi-monoubiquitylation of Snail1. Nat Cell Biol 19, 1260-1273
44. Ndubaku C and Tsui V (2015) Inhibiting the deubiquitinating enzymes (DUBs). J Med Chem 58, 1581-1593
45. D'Arcy P, Wang X and Linder S (2015) Deubiquitinase inhibition as a cancer therapeutic strategy. Pharmacol Ther 147, 32-54
46. Kaushal K, Antao AM, Kim KS and Ramakrishna S (2018) Deubiquitinating enzymes in cancer stem cells: functions and targeted inhibition for cancer therapy. Drug Discov Today 23, 1974-1982
47. Kaushal K, Antao AM, Kim KS and Ramakrishna S (2018) Deubiquitinating enzymes in cancer stem cells: functions and targeted inhibition for cancer therapy. Drug Discov Today 23, 1974-1982
48. Komander D (2009) The emerging complexity of protein ubiquitination. Cell 137, 21-34
49. Brnjic S, Mazurkiewicz M, Fryknäs M et al (2014) Deubiquitinating enzymes and targeted inhibition for cancer therapy. Pharmacol Ther 147, 32-54
50. Harrigan JA, Jacq X, Martin NM et al (2017) Deubiquitylating enzymes and drug discovery: emerging opportunities. Nat Rev Drug Discov 17, 57-78
51. Okada K, Ye YQ, Taniguchi K et al (2013) Vialinin A is a ubiquitin-specific peptidase inhibitor. Bioorg Med Chem Lett 23, 4328-4331
52. Yang J, Xu P, Han L et al (2015) Cutting Edge: Ubiquitin-Specific Protease 4 Promotes Th17 Cell Function under Inflammation by Deubiquitinating and Stabilizing RORγt. J Immunol 194, 4094-4097
53. Gavory G, O’dowd C, McClelland K et al (2015) Abstract LB-257: Discovery and characterization of novel, highly potent and selective USP7 inhibitors. Cancer Res 75, 15
54. Revery C, Conrath S, Lopez R et al (2012) Discovery of Specific Inhibitors of Human USP7/HAUSP Deubiquitinating Enzyme. Chem Biol 19, 467-477
55. Colland F, Formstecker E, Jacq X et al (2009) Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Mol Cancer Ther 8, 2286-2295
56. Weinstock J, Wu J, Cao P et al (2012) Selective Dual Inhibitors of the Cancer-Related Deubiquitinating Proteases USP7 and USP47. ACS Med Chem Lett 3, 789-792
57. Kapuria V, Peterson LF, Fang D, Bornmann WG, Talpaz M and Donato NJ (2010) Deubiquitination Inhibition by Small-Molecule WP1130 Triggers Aggresome Formation and Tumor Cell Apoptosis. Cancer Res 70, 9265-9276
58. Burkhardt RA, Peng Y, Norris ZA et al (2013) Mitoxantrone Targets Human Ubiquitin-Specific Peptidase 11 (USP11) and Is a Potent Inhibitor of Pancreatic Cancer Cell Survival. Mol Cancer Res 11, 901-911
59. Lee B-H, Lee MJ, Park S et al (2010) Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature 467, 179-184
60. Deng H, O’keeve H, Davie CP et al (2012) Discovery of Highly Potent and Selective Small Molecule ADAMTS-5 Inhibitors That Inhibit Human Cartilage Degradation via Encoded Library Technology (ELT). J Med Chem 55, 7061-7079
61. Yue W, Chen Z, Liu H et al (2014) A small natural molecule promotes mitochondrial fusion through inhibition of the deubiquitinase USP30. Cell Res 24, 482-496
62. Tian Z, D’Arcy P, Wang X et al (2014) A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood 123, 706-716
63. Gu Y, Ding X, Huang J et al (2018) The deubiquitinating enzyme UCHL1 negatively regulates the immunosuppressive capacity and survival of multipotent mesenchymal stromal cells. Cell Death Dis 9, 459
64. D’Arcy P, Wang X and Linder S (2015) Deubiquitinase inhibition as a cancer therapeutic strategy. Pharmacol Ther 147, 32-54
65. Lei H, Shan H and Wu Y (2017) Targeting deubiquitinating enzymes in cancer stem cells. Cancer Cell Int 17, 101
66. Zou Y, Qiu G, Jiang L et al (2017) Overexpression of ubiquitin specific protease 2a (USP2a) and nuclear factor erythroid 2-related factor 2 (Nrf2) in human gliomas. J Neurol Sci 363, 249-252
67. Zhang QX, Wang XC, Chen SP and Qin XT (2016) Predictive value of deubiquitination enzymes USP37 in the prognosis of breast cancer. Zhonghua Yi Xue Za Zhi 96, 944-948
68. Qu Q, Yao Y, Xiao G et al (2013) USP2 promotes cell migration and invasion in triple negative breast cancer cell lines. Tumor Biol 36, 5415-5423
69. Ni Q, Chen J, Li X et al (2017) Expression of OTU1B1 in hepatocellular carcinoma and its effects on HCC cell migration and invasion. Acta Biochim Biophys Sin (Shanghai) 49, 680-688
70. Liu R, Zhao D, Zhang X et al (2017) A20 enhances the radiosensitivity of hepatocellular carcinoma cells to 60Co-γ ionizing radiation. Oncotarget 8, 93103-93116
71. Yao R, Pu J, Fan R et al (2017) Ubiquitin-specific protease 4 improves the prognosis of the patients in esophageal cancer. Cancer Biomarkers 20, 317-323
72. Baykar M, Yaman M, Buyukberber S et al (2009) Clinical and prognostic importance of XIAP and USP8 in advanced stages of non-small cell lung cancer. J BUON 14, 921-927
73. Kim Y, Shiba-Ishii A, Nakagawa T et al (2017) Ubiquitin-specific protease 8 is a novel prognostic marker in early-stage lung adenocarcinoma. Pathol Int 67, 292-301
74. Zeng Z, Wu HX, Zhan N et al (2014) Prognostic significance of USP10 as a tumor-associated marker in gastric carcinoma. Tumor Biol 35, 3845-3853
75. Zhang B, Wang H, Yang L et al (2016) OTUD7B and NIK expression in non-small cell lung cancer: Association with clinicopathological features and prognostic implications. Pathol Res Pract 212, 893-898
76. McFarlane C, McFarlane S, Paul I et al (2013) The deubiquitinating enzyme USP17 is associated with non-small cell lung cancer (NSCLC) recurrence and metastasis. Oncotarget 4, 1836-1843
77. Peng L, Hu Y, Chen D, Jiao S and Sun S (2016) Ubiquitin-specific peptidase 21 regulates interleukin-8 expression, stem-cell like property of human renal cell carcinoma. Oncotarget 7, 42007-42016
78. Kim Y-H, Kim WT, Jeong P et al (2014) Ubiquitin-specific protease 8 is a novel prognostic marker in advanced stages of non-small cell lung cancer. Oncotarget 5, 6804-6812
79. Wang H, Li YP, Chen JH et al (2013) Prognostic implications of USP37 in patients with muscle invasive Bladder Cancer: USP18 and DGGCR2. J Korean Med Sci 29, 351
80. Yang M, Liu YD, Wang YY, Liu TB, Ge TT and Lou G (2014) Ubiquitin-specific peptidase 4 improves the prognosis of the patients in non-muscle invasive bladder cancer. Tumor Biol 35, 797-803
81. Piao S, Liu Y, Hu J et al (2012) USP22 Is Useful as a Molecular Marker for Predicting Survival in Patients with Muscle Invasive Bladder Cancer: USP18 and DGGCR2. J Korean Med Sci 29, 351
82. Jia M, Guo Y and Lu X (2018) USP33 is a Biomarker of a potential prognostic marker for bladder cancer. Tumor Biol 39, 929-934
83. Yang M, Liu YD, Wang YY, Liu TB, Ge TT and Lou G (2014) Ubiquitin-specific peptidase 21 regulates interleukin-8 expression, stem-cell like property of human renal cell carcinoma. Oncotarget 7, 42007-42016
84. Piao S, Liu Y, Hu J et al (2012) USP22 Is Useful as a Novel Molecular Marker for Predicting Disease Progression and Patient Prognosis of Oral Squamous Cell Carcinoma. PLoS One 7, e42540
85. Jia M, Guo Y and Lu X (2018) USP33 is a Biomarker of Disease Recurrence in Papillary Thyroid Carcinoma. Cell Physiol Biochem 45, 2044-2053
86. Lu H, Li YP, Chen JH et al (2017) Prognostic significance of USP22 as an oncogene in papillary thyroid carcinoma. Tumor Biol 38, 1635-1639
87. Guo G, Xu Y, Gong M, Cao Y and An R (2014) USP28 is a potential prognostic marker for bladder cancer. Tumor
DUBs as cancer biomarkers
Naresh Poondla, et al.

189 http://bmbreports.org

85. Li Y, Li J, Liu H, Liu Y and Cui B (2017) Expression of MYSM1 is associated with tumor progression in colorectal cancer. PLoS One 12, e0177235
86. Liu H, Zhang Q, Li K et al (2016) Prognostic significance of USP33 in advanced colorectal cancer patients: new insights into arrestin-dependent ERK signaling. Oncotarget 7, 81223-81240
87. Huang Y, Pan XW, Li L et al (2016) Overexpression of USP39 predicts poor prognosis and promotes tumorigenesis of prostate cancer via promoting EGFR mRNA maturation and transcription elongation. Oncotarget 7, 22016-22030
88. Testa JR, Cheung M, Pei J et al (2011) Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 43, 1022-1025
89. Chiu HW, Lin HY, Tseng IJ, Hsiao M and Lin YF (2018) OTUD7B upregulation predicts a poor response to paclitaxel in patients with triple-negative breast cancer. Oncotarget 9, 553-565
90. Arpalahti L, Saukkonen K, Hagström J et al (2017) Nuclear ubiquitin C-terminal hydrolase L5 expression associates with increased patient survival in pancreatic ductal adenocarcinoma. Tumor Biol 39, 101042831771041
91. Yang H, Zhang C, Fang S, Ou R, Li W and Xu Y (2015) UCH-L1 acts as a novel prognostic biomarker in gastric cardiac adenocarcinoma. Int J Clin Exp Pathol 8, 13957-13967
92. Hussain S, Bedekovics T, Chesi M, Bergsagel PL and Galardy PJ (2015) UCH-L1 is a biomarker of aggressive multiple myeloma required for disease progression.
93. Kwon J, Mochida K, Wang YL et al (2005) Ubiquitin C-Terminal Hydrolase L-1 Is Essential for the Early Apoptotic Wave of Germinal Cells and for Sperm Quality Control During Spermatogenesis. Biol Reprod 73, 29-35
94. Liu C, Liu C, Liu H et al (2017) Increased Expression of Ubiquitin-Specific Protease 4 Participates in Neuronal Apoptosis After Intracerebral Hemorrhage in Adult Rats. Cell Mol Neurobiol 37, 427-435
95. He B, Zhao YC, Gao LC et al (2016) Ubiquitin-Specific Protease 4 Is an Endogenous Negative Regulator of Pathological Cardiac Hypertrophy. Hypertension 67, 1237-1248
96. Oliveira AM and Chou MM (2014) USP6-induced neoplasms: the biologic spectrum of aneurysmal bone cyst and nodular fasciitis. Hum Pathol 45, 1-11
97. Brackeva B, De Punt V, Kramer G et al (2015) Potential of UCHL1 as biomarker for destruction of pancreatic beta cells. J Proteomics 117, 156-167
98. Lewis SB, Wolper R, Chi YY et al (2010) Identification and preliminary characterization of ubiquitin C terminal hydrolase 1 (UCHL1) as a biomarker of neuronal loss in aneurysmal subarachnoid hemorrhage. J Neurosci Res 88, 1475-1484
99. Papa L, Akinyi L, Liu MC et al (2010) Ubiquitin C-terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury. Crit Care Med 38, 138-144
100. Song YL, Yu R, Qiao X-W et al (2017) Prognostic relevance of UCH-L1 and α-internexin in pancreatic neuroendocrine tumors. Sci Rep 7, 2205